A Phase 3 interventional study of Tofacitinib 5 mg BID and Tofacitinib 10 mg BID in Psoriatic Arthritis, sponsored by Pfizer. Completed at 123 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-06.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing tofacitinib in Arthritis, Psoriatic — 2 open to participants now, 2 under way, 1 of them phase 3. tofacitinib · Arthritis, Psoriatic.
Among the 10 studies testing tofacitinib in Arthritis, Psoriatic, this one is the 3rd largest by enrollment, is one of 2 that started in 2014, is one of 7 in phase 3, and was the 2nd registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →2 of the 10 studies testing tofacitinib in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–75
By country, each count listing its studies:
tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 422 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 237 across the 10 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 10 have an industry lead sponsor. The 6 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
29 studies in Arthritis, Psoriatic by Pfizer: 1 open now, 1 under way, none of them phase 3. Of 28 finished, 22 (79%) have results posted.
Among the 29 studies in Arthritis, Psoriatic by Pfizer, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2014, is one of 6 in phase 3, and was the 16th registered.
Pfizer’s Arthritis, Psoriatic studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing tofacitinib in Arthritis, Psoriatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 29 in Arthritis, Psoriatic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a 12-month study investigating the effectiveness and safety of tofactinib in treating the signs and symptoms of active psoriatic arthritis and improving physical function and preserving bone structure in patients with an inadequate response to a traditional, nonbiologic disease-modifying antirheumatic drug. Adalimumab is used as a comparator.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tofacitinib 5 mg BID
Drug: Tofacitinib 10 mg BID
Drug: Adalimumab
Drug: Placebo
Drug: Placebo
Tofacitinib orally (po) 1 tablet of 5 mg and placebo po 1 tablet BID x 12 months Placebo injections subcu every 2 weeks x 12 months
Tofacitinib po 2 tablets of 5 mg BID x 12 months Placebo injections subcu every 2 weeks x 12 months
Placebo po 2 tablets BIDx 12 months Adalimumab 40 mg subcu injections every 2 weeks x 12 months
Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 1 tablet of 5 mg and placebo po 1 tablet BID x 9 months Placebo injections every 2 weeks x 12 months
Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 2 tablets (5 mg) BID x 9 months Placebo injections every 2 weeks x 12 months
Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥20% (ACR20): Month 3
ACR20 was calculated as a ≥20% improvement from baseline in tender/painful and swollen joint counts and ≥20% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, health assessment questionnaire - disability index (HAQ-DI), and C-reactive protein (CRP).
Time frame: At end of Month 3
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score
The HAQ-DI assesses the difficulty a participant has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability.
Time frame: From Baseline to Month 3
Change From Baseline in the Van Der Heijdel Modified Total Sharp Score (mTSS) for Psoriatic Arthritis
Assessment of joint damage includes a joint erosion score (range 0-320) and a joint space narrowing (JSN) score (range 0-208). The mTSS is the sum of the erosion and JSN scores (range 0-528). A higher score indicates more severe disease status. If a component score is missing, the mTSS will be missing.
Time frame: From Baseline to Month 12
Percentage of Participants With Progressed Modified Total Sharp Score (mTSS) at Month 12
Assessment of joint damage includes a joint erosion score (range 0-320) and a JSN score (range 0-208). The mTSS is the sum of the erosion and JSN scores (range 0-528). A higher score indicates more severe disease status. If a component score is missing, the mTSS will be missing. Progressor is defined as an increase in mTSS \>0.5 from baseline.
Time frame: At Month 12
Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, 6, 9, and 12
ACR50 was calculated as a ≥50% improvement from baseline in tender/painful and swollen joint counts and ≥50% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP.
Time frame: At Week 2 and Months 1, 2, 3, 4, 6, 9, and 12
Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, 6, 9, and 12
ACR70 was calculated as a ≥70% improvement from baseline in tender/painful and swollen joint counts and ≥70% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. .
Time frame: At Week 2 and Months 1, 2, 3, 4, 6, 9, and 12
Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥20% (ACR20) at Week 2 and Months 1, 2, 4, 6, 9, and 12
ACR20 was calculated as a ≥20% improvement from baseline in tender/painful and swollen joint counts and ≥20% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP.
Time frame: At Week 2 and Months 1, 2, 4, 6, 9, and 12
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score
The HAQ-DI assesses the difficulty a participant has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability.
Time frame: From Baseline to Week 2 and Months 1, 2, 4, 6, 9, and 12
Change From Baseline in American College of Rheumatology Response Criteria Components: C-reactive Protein Levels
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
Time frame: From Baseline to end of Month 3
Change From Baseline in American College of Rheumatology Response Criteria Components Score: Patient's Assessment of Arthritis Pain
Participants assessed the severity of their arthritis pain using a 100-mm visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain.
Time frame: From Baseline to end of Month 3
Change From Baseline in American College of Rheumatology Response Criteria Components Score: Patient's Global Assessment of Arthritis
Participant answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The participant's response was recorded using a 100 mm VAS by placing a mark on the scale between 0 (very well) and 100 (very poorly).
Time frame: From Baseline to end of Month 3
Change From Baseline in American College of Rheumatology Response Criteria Components Score: Physician's Global Assessment of Arthritis
The blinded investigator or qualified assessor assessed how the participant's overall arthritis appeared at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS by placing a mark on the scale between 0 (very good) and 100 (very poor).
Time frame: From Baseline to end of Month 3
Change From Baseline in American College of Rheumatology Response Criteria Components Score: Swollen Joint Count
Swollen joint counts are considered the most specific quantitative clinical measure used to assess the status of participants with inflammatory types of arthritis. Sixty six (66) joints were assessed by a blinded assessor to determine the number of joints that were considered swelling.
Time frame: From Baseline to end of Month 3
Change From Baseline in American College of Rheumatology Response Criteria Components Score: Tender/Painful Joint Count
Tender/painful joint counts are considered the most specific quantitative clinical measure used to assess the status of participants with inflammatory types of arthritis. Sixty eight (68) joints were assessed by a blinded assessor to determine the number of joints that were considered tender or painful.
Time frame: From Baseline to end of Month 3
Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC) at Week 2 and Months 1, 2, 3, 4, 6, 9, and 12
The PsARC covers 4 measures: Tender/painful joint count, swollen joint count, the Physician's Global Assessment of Arthritis, and the Patient's Global Assessment of Arthritis. The PsARC response is defined as improvement in 2 of 4 items, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement criteria: ≥20% improvement in Physician's Global Assessment of Arthritis; ≥20% improvement in Patient's Global Assessment of Arthritis; ≥30% improvement in tender joint count; and ≥30% improvement in swollen joint count.
Time frame: At Week 2 and Months 1, 2, 3, 4, 6, 9, and 12
Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response
The PGA-PsO is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are rated separately over the whole body according to a 5-point severity scale, scored as 0=none; 1, 2, 3, or 4=most severe. The severity rating scores are summed and the average taken; the total average is rounded to the nearest whole number score to determine a PGA-PsO score on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe).
Time frame: From Baseline to Months 1, 3, 6, 9, and 12
Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response at Months 1, 3, 6, 9, and 12
PASI determines psoriasis severity based on lesion severity \& percentage body surface area (BSA) affected. Lesion severity is assessed for erythema, induration, \& scaling, evaluated separately for head \& neck, upper limbs, trunk, \& lower limbs \& rated for each body area according to a 5 point scale: 0=no involvement; 1=slight; 2=moderate; 3=marked; 4=very marked. BSA involvement is the extent (%) of body area affected by psoriasis \& is assigned a score: 0=no involvement; 1=0-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100%. In each area, sum of severity rating scores is multiplied by the score representing the percentage of area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of numbers obtained for the 4 body areas is the PASI score \& can vary in increments of 0.1 \& range from 0.0 to 72.0, higher scores represent greater severity of psoriasis. PASI75 is defined as a 75% reduction from baseline in PASI.
Time frame: At Months 1, 3, 6, 9, and 12
Change From Baseline in Dactylitis Severity Score (DSS)
Dactylitis is characterized by swelling of the entire finger or toe. The DSS is a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis is scored on a scale of 0-3, where 0=no tenderness and 3=extreme tenderness in each digit of the hands and feet. The range of total dactylitis scores for a patient is 0-60. Higher score indicates greater degree of tenderness.
Time frame: From Baseline to Months 1, 3, 6, 9, and 12
Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index
The SPARCC Enthesitis Index identifies the presence or absence of tenderness at 16 enthesial sites, including the bilateral Achilles tendons, plantar fascia insertion at the calcaneus, patellar tendon insertion at the base of the patella, quadriceps insertion into the superior border of the patella, supraspinatus insertion into the greater tuberosity of the humerus, and medial and lateral epicondyles. On examination, tenderness is recorded as present (1) or absent (0) for each of the 16 sites, with an overall total score ranging from 0 to 16. Higher score indicates a greater number of sites that are affected by enthesitis.
Time frame: From Baseline to Months 1, 3, 6, 9, and 12
Change From Baseline in the Leeds Enthesitis Index (LEI)
Enthesitis is inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assesses enthesitis in 6 sites. Tenderness is recorded as either present (1) or absent (0) for each of the 6 sites, for an total score of 0-6. Higher score indicates a greater number of sites that are affected by enthesitis.
Time frame: From Baseline to Months 1, 3, 6, 9, and 12
Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2) Acute, Physical Component Summary Score
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the physical component summary (PCS) score and the mental component summary (MCS) score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a standard deviation (SD) of 10 points, and ranges from minus infinity to plus infinity. A higher PCS score represents better physical health status.
Time frame: From Baseline to Months 1, 3, 6, 9, and 12
Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute, Mental Component Summary Score
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher MCS score represents better mental health status.
Time frame: From Baseline to Months 1, 3, 6, 9, and 12
Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Physical Functioning Domain
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher physical functioning domain score represents better physical functioning.
Time frame: From Baseline to Months 1, 3, 6, 9, and 12
Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Role-Physical Domain
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher role-physical domain score represents better role-physical functioning.
Time frame: From Baseline to Months 1, 3, 6, 9, and 12
Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Bodily Pain Domain
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher bodily pain domain score represents less bodily pain.
Time frame: From Baseline to Months 1, 3, 6, 9, and 12
Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: General Health Domain
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher general health domain score represents better general health perceptions.
Time frame: From Baseline to Months 1, 3, 6, 9, and 12
Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Vitality Domain
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher vitality domain score represents better vitality.
Time frame: From Baseline to Months 1, 3, 6, 9, and 12
Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Social Functioning Domain
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher social functioning domain score represents better social functioning.
Time frame: From Baseline to Months 1, 3, 6, 9, and 12
Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Role-Emotional Domain
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher role-emotional domain score represents better role-emotional functioning.
Time frame: From Baseline to Months 1, 3, 6, 9, and 12
Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Mental Health Domain
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher mental health domain score represents better mental health functioning.
Time frame: From Baseline to Months 1, 3, 6, 9, and 12
Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility
The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems \[1\], some or moderate problems \[2\], or extreme problems \[3\]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.
Time frame: From Baseline to Months 1, 3, 6, 9, and 12
Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-care
The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems \[1\], some or moderate problems \[2\], or extreme problems \[3\]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.
Time frame: From Baseline to Months 1, 3, 6, 9, and 12
Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities
The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems \[1\], some or moderate problems \[2\], or extreme problems \[3\]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.
Time frame: From Baseline to Months 1, 3, 6, 9, and 12
Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort
The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems \[1\], some or moderate problems \[2\], or extreme problems \[3\]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.
Time frame: From Baseline to Months 1, 3, 6, 9, and 12
Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression
The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems \[1\], some or moderate problems \[2\], or extreme problems \[3\]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.
Time frame: From Baseline to Months 1, 3, 6, 9, and 12
Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today
The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems \[1\], some or moderate problems \[2\], or extreme problems \[3\]) within a particular EQ-5D dimension. Standard vertical 0 (worst imaginable health state) to 100 mm (best imaginable health state) visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state; higher scores indicate a better health state, with a higher value representing better health status.
Time frame: From Baseline to Months 1, 3, 6, 9, and 12
Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score
FACIT-F is a 13-item questionnaire, with each item scored on a 5-point scale ranging from 0 (not at all) to 4 (very much). Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0 to 52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better fatigue status.
Time frame: From Baseline to Months 1, 3, 6, 9, and 12
Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score
FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better (less) fatigue experience.
Time frame: From Baseline to Months 1, 3, 6, 9, and 12
Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score
FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better (less) fatigue impact on daily functioning.
Time frame: From Baseline to Months 1, 3, 6, 9, and 12
Change From Baseline in Scores Evaluating Spondylitis Using the Bath Anklyosing Spondylitis Disease Activity Index (BASDAI)
BASDAI is a validated self-assessment tool used to determine disease activity in participants with ankylosing spondylitis. Utilizing a visual analog scale of 0-100mm (0=none and 100=very severe) participants answer 6 questions measuring discomfort, pain, and fatigue. The final BASDAI score averages the individual assessments for a final score ranging 0-10cm, with higher scores representing more severe ankylosing spondylitis disease activity.
Time frame: From Baseline to Months 1, 3, 6, 9, and 12
| Milestone | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily |
|---|---|---|---|---|---|
| Started | 107 | 104 | 106 | 52 | 53 |
| Completed | 96 | 96 | 94 | 44 | 43 |
| Not completed | 11 | 8 | 12 | 8 | 10 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 0 |
| Withdrew: No longer met study criteria | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Insufficient clinical response | 0 | 1 | 2 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 3 | 2 | 2 |
| Withdrew: Other | 1 | 1 | 1 | 1 | 3 |
| Withdrew: Protocol violation | 1 | 1 | 0 | 0 | 3 |
| Withdrew: Adverse event related to study drug | 2 | 2 | 2 | 2 | 1 |
| Withdrew: Adverse event unrelated to study drug | 4 | 1 | 2 | 0 | 1 |
ACR20 was calculated as a ≥20% improvement from baseline in tender/painful and swollen joint counts and ≥20% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, health assessment questionnaire - disability index (HAQ-DI), and C-reactive protein (CRP).
| Percentage or participants | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo |
|---|---|---|---|---|
| Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥20% (ACR20): Month 3 | 50.47 | 60.58 | 51.89 | 33.33 |
The HAQ-DI assesses the difficulty a participant has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability.
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo |
|---|---|---|---|---|
| Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score | -0.3499 ± 0.04665 | -0.3998 ± 0.04716 | -0.3808 ± 0.04767 | -0.1802 ± 0.05031 |
Assessment of joint damage includes a joint erosion score (range 0-320) and a joint space narrowing (JSN) score (range 0-208). The mTSS is the sum of the erosion and JSN scores (range 0-528). A higher score indicates more severe disease status. If a component score is missing, the mTSS will be missing.
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily |
|---|---|---|---|---|---|
| Change From Baseline in the Van Der Heijdel Modified Total Sharp Score (mTSS) for Psoriatic Arthritis | 0.01 ± 0.067 | -0.01 ± 0.067 | -0.07 ± 0.069 | 0.00 ± 0.094 | 0.09 ± 0.099 |
Assessment of joint damage includes a joint erosion score (range 0-320) and a JSN score (range 0-208). The mTSS is the sum of the erosion and JSN scores (range 0-528). A higher score indicates more severe disease status. If a component score is missing, the mTSS will be missing. Progressor is defined as an increase in mTSS \>0.5 from baseline.
| Percentage of participants | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily |
|---|---|---|---|---|---|
| Percentage of Participants With Progressed Modified Total Sharp Score (mTSS) at Month 12 | 4.08 | 5.05 | 2.11 | 4.17 | 8.89 |
ACR50 was calculated as a ≥50% improvement from baseline in tender/painful and swollen joint counts and ≥50% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP.
| Percentage of participants | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Week 2 (n=7, 7, 5, NA, NA, 1) | 6.54 | 6.73 | 4.72 | NA | NA | 0.95 |
| Month 1 (n=13, 20,12, NA, NA, 5) | 12.15 | 19.23 | 11.32 | NA | NA | 4.76 |
| Month 2 (n=23, 34, 24, NA, NA, 8) | 21.50 | 32.69 | 22.64 | NA | NA | 7.62 |
| Month 3 (n=30, 42, 35, NA, NA, 10) | 28.04 | 40.38 | 33.02 | NA | NA | 9.52 |
| Month 4 (n=38, 39, 34, 11, 17, NA) | 35.51 | 37.50 | 32.08 | 21.15 | 32.08 | NA |
| Month 6 (n=41, 48, 45, 17, 14, NA) | 38.32 | 46.15 | 42.45 | 32.69 | 26.42 | NA |
| Month 9 (n=45, 48, 49, 22, 23, NA) | 42.06 | 46.15 | 46.23 | 42.31 | 43.40 | NA |
| Month 12 (n=48, 50, 43, 21, 19, NA) | 44.86 | 48.08 | 40.57 | 40.38 | 35.85 | NA |
ACR70 was calculated as a ≥70% improvement from baseline in tender/painful and swollen joint counts and ≥70% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. .
| Percentage of participants | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Week 2 (n=0, 3, 1, NA, NA, 0) | 0.00 | 2.88 | 0.94 | NA | NA | 0.00 |
| Month 1 (n=5, 8, 4, NA, NA, 1) | 4.67 | 7.69 | 3.77 | NA | NA | 0.95 |
| Month 2 (n=10, 14, 13, NA, NA, 2) | 9.35 | 13.46 | 12.26 | NA | NA | 1.90 |
| Month 3 (n=18, 15, 20, NA, NA, 5) | 16.82 | 14.42 | 18.87 | NA | NA | 4.76 |
| Month 4 (n=24, 23, 21, 7, 8, NA) | 22.43 | 22.12 | 19.81 | 13.46 | 15.09 | NA |
| Month 6 (n=19, 33, 32, 10, 7, NA) | 17.76 | 31.73 | 30.19 | 19.23 | 13.21 | NA |
| Month 9 (n=21, 31, 30, 15, 12, NA) | 19.63 | 29.81 | 28.30 | 28.85 | 22.64 | NA |
| Month 12 (n=25, 32, 31, 12, 12, NA) | 23.36 | 30.77 | 29.25 | 23.08 | 22.64 | NA |
ACR20 was calculated as a ≥20% improvement from baseline in tender/painful and swollen joint counts and ≥20% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP.
| Percentage of participants | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Week 2 (n=24, 33, 23, NA, NA, 6) | 22.43 | 31.73 | 21.70 | NA | NA | 5.71 |
| Month 1 (n=37, 50, 30, NA, NA, 11) | 34.58 | 48.08 | 28.30 | NA | NA | 10.48 |
| Month 2 (n=47, 57, 62, NA, NA, 28) | 43.93 | 54.81 | 58.49 | NA | NA | 26.67 |
| Month 4 (n=65, 60, 61, 27, 28, NA) | 60.75 | 57.69 | 57.55 | 51.92 | 52.83 | NA |
| Month 6 (n=63, 70, 68, 31, 30, NA) | 58.88 | 67.31 | 64.15 | 59.62 | 56.60 | NA |
| Month 9 (n=73, 76, 73, 35, 37, NA) | 68.22 | 73.08 | 68.87 | 67.31 | 69.81 | NA |
| Month 12 (n=73, 73, 64, 35, 31, NA) | 68.22 | 70.19 | 60.38 | 67.31 | 58.49 | NA |
The HAQ-DI assesses the difficulty a participant has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability.
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Week 2 (n=106, 102, 103, NA, NA, 102) | -0.1842 ± 0.04131 | -0.2089 ± 0.04208 | -0.2129 ± 0.04246 | NA ± NA | NA ± NA | -0.0837 ± 0.04549 |
| Month 1 (n=105, 103, 104, NA, NA, 103) | -0.2048 ± 0.04363 | -0.2676 ± 0.04426 | -0.3028 ± 0.04465 | NA ± NA | NA ± NA | -0.1224 ± 0.04755 |
| Month 2 (n=104, 104, 104, NA, NA, 102) | -0.2713 ± 0.04626 | -0.4009 ± 0.04678 | -0.3736 ± 0.04719 | NA ± NA | NA ± NA | -0.1682 ± 0.04998 |
| Month 4 (n=102, 100, 102, 50, 50, NA) | -0.4231 ± 0.04982 | -0.4407 ± 0.05039 | -0.3643 ± 0.05069 | -0.2850 ± 0.07075 | -0.3302 ± 0.07128 | NA ± NA |
| Month 6 (n=100, 100, 99, 48, 48, NA) | -0.4471 ± 0.05136 | -0.4611 ± 0.05179 | -0.4259 ± 0.05227 | -0.3142 ± 0.07315 | -0.3841 ± 0.07369 | NA ± NA |
| Month 9 (n=99, 96, 96, 47, 45, NA) | -0.5119 ± 0.05038 | -0.4847 ± 0.05096 | -0.4304 ± 0.05143 | -0.3843 ± 0.07185 | -0.4839 ± 0.07276 | NA ± NA |
| Month 12 (n=96, 96, 94, 44, 44, NA) | -0.5391 ± 0.05324 | -0.5104 ± 0.05365 | -0.4478 ± 0.05426 | -0.4104 ± 0.07646 | -0.4569 ± 0.07704 | NA ± NA |
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
| mg/L | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo |
|---|---|---|---|---|
| Change From Baseline in American College of Rheumatology Response Criteria Components: C-reactive Protein Levels | -5.5981 ± 0.80656 | -6.6004 ± 0.80822 | -7.8955 ± 0.82547 | -0.8643 ± 0.86304 |
Participants assessed the severity of their arthritis pain using a 100-mm visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain.
| mm | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo |
|---|---|---|---|---|
| Change From Baseline in American College of Rheumatology Response Criteria Components Score: Patient's Assessment of Arthritis Pain | -21.49 ± 2.325 | -27.10 ± 2.342 | -21.87 ± 2.389 | -10.22 ± 2.499 |
Participant answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The participant's response was recorded using a 100 mm VAS by placing a mark on the scale between 0 (very well) and 100 (very poorly).
| mm | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo |
|---|---|---|---|---|
| Change From Baseline in American College of Rheumatology Response Criteria Components Score: Patient's Global Assessment of Arthritis | -20.08 ± 2.275 | -25.50 ± 2.291 | -21.47 ± 2.328 | -11.40 ± 2.439 |
The blinded investigator or qualified assessor assessed how the participant's overall arthritis appeared at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS by placing a mark on the scale between 0 (very good) and 100 (very poor).
| mm | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo |
|---|---|---|---|---|
| Change From Baseline in American College of Rheumatology Response Criteria Components Score: Physician's Global Assessment of Arthritis | -27.44 ± 1.998 | -33.74 ± 2.021 | -29.02 ± 2.043 | -22.26 ± 2.121 |
Swollen joint counts are considered the most specific quantitative clinical measure used to assess the status of participants with inflammatory types of arthritis. Sixty six (66) joints were assessed by a blinded assessor to determine the number of joints that were considered swelling.
| Joints | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo |
|---|---|---|---|---|
| Change From Baseline in American College of Rheumatology Response Criteria Components Score: Swollen Joint Count | -6.5 ± 0.58 | -7.6 ± 0.58 | -6.5 ± 0.59 | -4.8 ± 0.62 |
Tender/painful joint counts are considered the most specific quantitative clinical measure used to assess the status of participants with inflammatory types of arthritis. Sixty eight (68) joints were assessed by a blinded assessor to determine the number of joints that were considered tender or painful.
| Joints | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo |
|---|---|---|---|---|
| Change From Baseline in American College of Rheumatology Response Criteria Components Score: Tender/Painful Joint Count | -8.7 ± 1.04 | -11.0 ± 1.05 | -7.6 ± 1.07 | -6.9 ± 1.10 |
The PsARC covers 4 measures: Tender/painful joint count, swollen joint count, the Physician's Global Assessment of Arthritis, and the Patient's Global Assessment of Arthritis. The PsARC response is defined as improvement in 2 of 4 items, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement criteria: ≥20% improvement in Physician's Global Assessment of Arthritis; ≥20% improvement in Patient's Global Assessment of Arthritis; ≥30% improvement in tender joint count; and ≥30% improvement in swollen joint count.
| Percentage of participants | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Week 2 (n=34, 42, 23, NA, NA, 10) | 31.78 | 40.38 | 21.70 | NA | NA | 9.52 |
| Month 1 (n=45, 51, 43, NA, NA, 23) | 42.06 | 49.04 | 40.57 | NA | NA | 21.90 |
| Month 2 (n=54, 69, 62, NA, NA, 36) | 50.47 | 66.35 | 58.49 | NA | NA | 34.29 |
| Month 3 (n=55, 73, 65, NA, NA, 47) | 51.40 | 70.19 | 61.32 | NA | NA | 44.76 |
| Month 4 (n=68, 68, 71, 32, 30, NA) | 63.55 | 65.38 | 66.98 | 61.54 | 56.60 | NA |
| Month 6 (n=61, 75, 71, 35, 35, NA) | 57.01 | 72.12 | 66.98 | 67.31 | 66.04 | NA |
| Month 9 (n=75, 73, 71, 36, 37, NA) | 70.09 | 70.19 | 66.98 | 69.23 | 69.81 | NA |
| Month 12 (n=69, 76, 69, 39, 33, NA) | 64.49 | 73.08 | 65.09 | 75.00 | 62.26 | NA |
The PGA-PsO is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are rated separately over the whole body according to a 5-point severity scale, scored as 0=none; 1, 2, 3, or 4=most severe. The severity rating scores are summed and the average taken; the total average is rounded to the nearest whole number score to determine a PGA-PsO score on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe).
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=100, 96, 100, NA, NA, 99) | -0.7 ± 0.07 | -0.8 ± 0.08 | -0.5 ± 0.08 | NA ± NA | NA ± NA | -0.2 ± 0.08 |
| Month 3 (n=98, 97, 98, NA, NA, 98) | -1.0 ± 0.08 | -1.2 ± 0.08 | -1.0 ± 0.09 | NA ± NA | NA ± NA | -0.4 ± 0.09 |
| Month 6 (n=96, 94, 96, 46, 46, NA) | -0.9 ± 0.09 | -1.3 ± 0.09 | -1.2 ± 0.09 | -0.7 ± 0.12 | -0.9 ± 0.13 | NA ± NA |
| Month 9 (n=95, 91, 94, 45, 44, NA) | -1.0 ± 0.09 | -1.5 ± 0.09 | -1.2 ± 0.09 | -0.7 ± 0.12 | -1.3 ± 0.13 | NA ± NA |
| Month 12 (n=91, 90, 92, 41, 43, NA) | -1.2 ± 0.09 | -1.5 ± 0.09 | -1.2 ± 0.09 | -0.9 ± 0.13 | -1.3 ± 0.13 | NA ± NA |
PASI determines psoriasis severity based on lesion severity \& percentage body surface area (BSA) affected. Lesion severity is assessed for erythema, induration, \& scaling, evaluated separately for head \& neck, upper limbs, trunk, \& lower limbs \& rated for each body area according to a 5 point scale: 0=no involvement; 1=slight; 2=moderate; 3=marked; 4=very marked. BSA involvement is the extent (%) of body area affected by psoriasis \& is assigned a score: 0=no involvement; 1=0-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100%. In each area, sum of severity rating scores is multiplied by the score representing the percentage of area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of numbers obtained for the 4 body areas is the PASI score \& can vary in increments of 0.1 \& range from 0.0 to 72.0, higher scores represent greater severity of psoriasis. PASI75 is defined as a 75% reduction from baseline in PASI.
| Percentage of participants | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=19, 19, 11, NA, NA, 4) | 23.17 ± 4.66 | 27.14 ± 5.32 | 14.29 ± 3.99 | NA ± NA | NA ± NA | 4.88 ± 2.38 |
| Month 3 (n=35, 31, 30, NA, NA, 12) | 42.68 ± 5.46 | 44.29 ± 5.94 | 38.96 ± 5.56 | NA ± NA | NA ± NA | 14.63 ± 3.90 |
| Month 6 (n=38, 42, 42, 12, 17, NA) | 46.34 ± 5.51 | 60.00 ± 5.86 | 54.55 ± 5.67 | 28.57 ± 6.97 | 42.50 ± 7.82 | NA ± NA |
| Month 9 (n=36, 48, 45, 14, 20, NA) | 43.90 ± 5.448 | 68.57 ± 5.55 | 58.44 ± 5.62 | 33.33 ± 7.27 | 50.00 ± 7.91 | NA ± NA |
| Month 12 (n=46, 47, 43, 15, 21, NA) | 56.10 ± 5.48 | 67.14 ± 5.61 | 55.84 ± 5.66 | 35.71 ± 7.39 | 52.50 ± 7.90 | NA ± NA |
Dactylitis is characterized by swelling of the entire finger or toe. The DSS is a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis is scored on a scale of 0-3, where 0=no tenderness and 3=extreme tenderness in each digit of the hands and feet. The range of total dactylitis scores for a patient is 0-60. Higher score indicates greater degree of tenderness.
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=58, 59, 56, NA, NA, 56) | -1.8 ± 0.91 | -3.1 ± 0.87 | -2.1 ± 0.93 | NA ± NA | NA ± NA | 0.6 ± 1.02 |
| Month 3 (n=58, 60 , 56, NA, NA, 55) | -3.5 ± 0.95 | -5.5 ± 0.91 | -4.0 ± 0.97 | NA ± NA | NA ± NA | -2.0 ± 1.06 |
| Month 6 (n=58, 59, 55, 28, 25, NA) | -5.2 ± 1.01 | -6.4 ± 0.99 | -5.4 ± 1.03 | -5.9 ± 1.45 | -5.2 ± 1.50 | NA ± NA |
| Month 9 (n=57, 59, 53, 27, 25, NA) | -7.0 ± 0.60 | -7.2 ± 0.58 | -6.5 ± 0.63 | -5.3 ± 0.87 | -7.9 ± 0.89 | NA ± NA |
| Month 12 (n=54, 58, 52, 26, 24, NA) | -7.4 ± 0.65 | -7.5 ± 0.62 | -6.1 ± 0.67 | -6.7 ± 0.93 | -7.7 ± 0.96 | NA ± NA |
The SPARCC Enthesitis Index identifies the presence or absence of tenderness at 16 enthesial sites, including the bilateral Achilles tendons, plantar fascia insertion at the calcaneus, patellar tendon insertion at the base of the patella, quadriceps insertion into the superior border of the patella, supraspinatus insertion into the greater tuberosity of the humerus, and medial and lateral epicondyles. On examination, tenderness is recorded as present (1) or absent (0) for each of the 16 sites, with an overall total score ranging from 0 to 16. Higher score indicates a greater number of sites that are affected by enthesitis.
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=79, 80, 80, NA, NA, 78) | -0.83 ± 0.317 | -1.27 ± 0.321 | -0.95 ± 0.336 | NA ± NA | NA ± NA | -0.58 ± 0.355 |
| Month 3 (n=77, 79, 79, NA, NA, 78) | -1.84 ± 0.363 | -2.41 ± 0.364 | -1.90 ± 0.375 | NA ± NA | NA ± NA | -1.17 ± 0.393 |
| Month 6 (n=76, 78, 76, 33, 39, NA) | -2.4 ± 0.34 | -2.6 ± 0.34 | -2.3 ± 0.35 | -2.4 ± 0.50 | -2.5 ± 0.48 | NA ± NA |
| Month 9 (n=75, 75, 73, 34, 37, NA) | -2.9 ± 0.31 | -2.6 ± 0.32 | -3.0 ± 0.33 | -2.8 ± 0.46 | -3.2 ± 0.44 | NA ± NA |
| Month 12 (n=72, 73, 72, 31, 37, NA) | -3.2 ± 0.33 | -3.1 ± 0.33 | -2.8 ± 0.35 | -2.5 ± 0.49 | -3.2 ± 0.46 | NA ± NA |
Enthesitis is inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assesses enthesitis in 6 sites. Tenderness is recorded as either present (1) or absent (0) for each of the 6 sites, for an total score of 0-6. Higher score indicates a greater number of sites that are affected by enthesitis.
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=74, 63, 75, NA, NA, 65) | -0.41 ± 0.192 | -0.57 ± 0.213 | -0.42 ± 0.203 | NA ± NA | NA ± NA | -0.26 ± 0.219 |
| Month 3 (n=70, 63, 73, NA, NA, 63) | -0.82 ± 0.221 | -1.46 ± 0.240 | -1.10 ± 0.228 | NA ± NA | NA ± NA | -0.43 ± 0.246 |
| Month 6 (n=72, 61, 71, 27, 31, NA) | -1.3 ± 0.21 | -1.2 ± 0.23 | -1.3 ± 0.22 | -1.0 ± 0.32 | -1.3 ± 0.30 | NA ± NA |
| Month 9 (n=70, 58, 68, 27, 29, NA) | -1.4 ± 0.20 | -1.3 ± 0.23 | -1.5 ± 0.21 | -1.4 ± 0.31 | -1.7 ± 0.30 | NA ± NA |
| Month 12 (n=67, 56, 67, 24, 29, NA) | -1.7 ± 0.19 | -1.6 ± 0.21 | -1.6 ± 0.20 | -1.4 ± 0.30 | -1.9 ± 0.28 | NA ± NA |
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the physical component summary (PCS) score and the mental component summary (MCS) score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a standard deviation (SD) of 10 points, and ranges from minus infinity to plus infinity. A higher PCS score represents better physical health status.
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=105, 103,104, NA, NA, 103) | 3.39 ± 0.638 | 4.66 ± 0.645 | 4.00 ± 0.655 | NA ± NA | NA ± NA | 1.54 ± 0.700 |
| Month 3 (n=102, 103,100, NA, NA, 102) | 5.51 ± 0.733 | 5.69 ± 0.735 | 6.23 ± 0.748 | NA ± NA | NA ± NA | 2.68 ± 0.785 |
| Month 6 (n=100, 100, 98, 48, 48, NA) | 6.72 ± 0.773 | 6.70 ± 0.777 | 6.26 ± 0.788 | 5.86 ± 1.101 | 6.07 ± 1.112 | NA ± NA |
| Month 9 (n=99, 97, 95, 47, 46, NA) | 7.52 ± 0.781 | 7.21 ± 0.787 | 6.91 ± 0.798 | 6.16 ± 1.115 | 7.15 ± 1.130 | NA ± NA |
| Month 12 (n=96, 96, 94, 44, 43, NA) | 7.61 ± 0.806 | 7.67 ± 0.810 | 6.74 ± 0.822 | 5.82 ± 1.160 | 5.72 ± 1.177 | NA ± NA |
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher MCS score represents better mental health status.
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=105, 103,104,NA, NA, 103) | 4.12 ± 0.841 | 3.63 ± 0.849 | 2.13 ± 0.871 | NA ± NA | NA ± NA | 3.19 ± 0.917 |
| Month 3 (n=102, 103,100, NA, NA, 102) | 4.35 ± 0.909 | 4.20 ± 0.909 | 3.13 ± 0.938 | NA ± NA | NA ± NA | 3.27 ± 0.976 |
| Month 6 (n=100, 100, 98, 48, 48, NA) | 5.70 ± 0.927 | 5.51 ± 0.930 | 4.58 ± 0.955 | 4.50 ± 1.319 | 3.62 ± 1.331 | NA ± NA |
| Month 9 (n=99, 97, 95, 47, 46, NA) | 5.07 ± 0.974 | 6.20 ± 0.982 | 3.68 ± 1.005 | 4.61 ± 1.391 | 6.03 ± 1.409 | NA ± NA |
| Month 12 (n=96, 96, 94, 44, 43, NA) | 4.82 ± 1.012 | 6.26 ± 1.016 | 4.81 ± 1.039 | 4.51 ± 1.455 | 4.43 ± 1.474 | NA ± NA |
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher physical functioning domain score represents better physical functioning.
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=105, 103,104, NA, NA, 103) | 2.43 ± 0.768 | 3.89 ± 0.776 | 2.81 ± 0.787 | NA ± NA | NA ± NA | 1.10 ± 0.840 |
| Month 3 (n=102, 103,101, NA, NA, 102) | 5.17 ± 0.846 | 5.23 ± 0.848 | 5.22 ± 0.862 | NA ± NA | NA ± NA | 2.06 ± 0.910 |
| Month 6 (n=100, 100, 99, 48, 48, NA) | 7.02 ± 0.897 | 6.15 ± 0.900 | 6.36 ± 0.912 | 5.22 ± 1.276 | 5.22 ± 1.291 | NA ± NA |
| Month 9 (n=99, 97, 96, 47, 46, NA) | 7.43 ± 0.902 | 6.67 ± 0.909 | 7.01 ± 0.921 | 5.69 ± 1.285 | 6.25 ± 1.306 | NA ± NA |
| Month 12 (n=96, 96, 94, 44, 44, NA) | 7.67 ± 0.899 | 7.11 ± 0.903 | 6.81 ± 0.917 | 6.49 ± 1.292 | 4.77 ± 1.308 | NA ± NA |
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher role-physical domain score represents better role-physical functioning.
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=105, 103,104, NA, NA, 103) | 4.05 ± 0.751 | 3.72 ± 0.759 | 4.09 ± 0.770 | NA ± NA | NA ± NA | 1.98 ± 0.820 |
| Month 3 (n=102, 103, 100, NA, NA, 102) | 4.45 ± 0.801 | 4.79 ± 0.803 | 5.21 ± 0.820 | NA ± NA | NA ± NA | 3.63 ± 0.862 |
| Month 6 (n=100, 100, 99, 48, 48, NA) | 6.02 ± 0.824 | 5.21 ± 0.828 | 5.48 ± 0.840 | 4.97 ± 1.172 | 5.03 ± 1.185 | NA ± NA |
| Month 9 (n=99, 97, 96, 47, 46, NA) | 6.24 ± 0.853 | 6.56 ± 0.861 | 5.79 ± 0.872 | 4.68 ± 1.217 | 6.70 ± 1.234 | NA ± NA |
| Month 12 (n=96, 96, 94, 44, 44, NA) | 6.21 ± 0.888 | 7.11 ± 0.892 | 6.37 ± 0.906 | 2.98 ± 1.279 | 5.03 ± 1.291 | NA ± NA |
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher bodily pain domain score represents less bodily pain.
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=105, 103,104, NA, NA, 103) | 5.53 ± 0.777 | 7.16 ± 0.786 | 6.42 ± 0.802 | NA ± NA | NA ± NA | 3.44 ± 0.851 |
| Month 3 (n=102, 103, 101, NA, NA, 102) | 7.75 ± 0.838 | 8.05 ± 0.840 | 7.52 ± 0.859 | NA ± NA | NA ± NA | 3.77 ± 0.903 |
| Month 6 (n=100, 100, 99, 48, 48, NA) | 7.76 ± 0.985 | 10.65 ± 0.989 | 7.76 ± 1.004 | 8.55 ± 1.405 | 8.98 ± 1.425 | NA ± NA |
| Month 9 (n=99, 97, 96, 47, 46, NA) | 9.03 ± 0.953 | 10.13 ± 0.960 | 8.59 ± 0.977 | 8.46 ± 1.362 | 10.81 ± 1.389 | NA ± NA |
| Month 12 (n=96, 96, 94, 44, 43, NA) | 9.15 ± 0.961 | 11.38 ± 0.965 | 9.18 ± 0.984 | 8.59 ± 1.384 | 8.61 ± 1.413 | NA ± NA |
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher general health domain score represents better general health perceptions.
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=105, 103,104, NA, NA, 103) | 3.29 ± 0.610 | 3.87 ± 0.616 | 1.96 ± 0.625 | NA ± NA | NA ± NA | 2.15 ± 0.666 |
| Month 3 (n=102, 103,101, NA, NA, 102 ) | 4.09 ± 0.700 | 3.95 ± 0.701 | 4.73 ± 0.713 | NA ± NA | NA ± NA | 2.64 ± 0.748 |
| Month 6 (n=100, 100, 99, 48, 48, NA) | 5.96 ± 0.720 | 4.12 ± 0.722 | 4.81 ± 0.733 | 4.39 ± 1.022 | 3.92 ± 1.033 | NA ± NA |
| Month 9 (n=99, 97, 96, 47, 46, NA) | 5.93 ± 0.773 | 5.18 ± 0.778 | 4.09 ± 0.788 | 4.72 ± 1.102 | 4.85 ± 1.117 | NA ± NA |
| Month 12 (n=96, 96, 94, 44, 44, NA) | 5.70 ± 0.811 | 4.63 ± 0.815 | 4.21 ± 0.825 | 4.50 ± 1.164 | 4.12 ± 1.175 | NA ± NA |
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher vitality domain score represents better vitality.
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=105, 103,104, NA, NA, 103) | 3.64 ± 0.802 | 4.59 ± 0.806 | 2.42 ± 0.826 | NA ± NA | NA ± NA | 2.16 ± 0.877 |
| Month 3 (n=102, 103, 101, NA, NA, 102) | 5.50 ± 0.889 | 5.90 ± 0.887 | 4.93 ± 0.909 | NA ± NA | NA ± NA | 3.05 ± 0.954 |
| Month 6 (n=100, 100, 99, 48, 48, NA) | 6.81 ± 0.969 | 7.41 ± 0.970 | 5.05 ± 0.989 | 5.34 ± 1.378 | 4.62 ± 1.394 | NA ± NA |
| Month 9 (n=99, 97, 96, 47, 46, NA) | 6.09 ± 1.017 | 7.82 ± 1.023 | 5.27 ± 1.041 | 6.61 ± 1.451 | 6.39 ± 1.472 | NA ± NA |
| Month 12 (n=96, 96, 94, 44, 44, NA) | 7.01 ± 1.022 | 7.02 ± 1.024 | 5.12 ± 1.043 | 5.62 ± 1.465 | 5.15 ± 1.481 | NA ± NA |
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher social functioning domain score represents better social functioning.
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=105, 103,104, NA, NA, 103) | 4.51 ± 0.827 | 4.46 ± 0.838 | 3.34 ± 0.852 | NA ± NA | NA ± NA | 2.96 ± 0.901 |
| Month 3 (n=102, 103, 101, NA, NA, 102) | 5.95 ± 0.897 | 5.22 ± 0.898 | 5.26 ± 0.918 | NA ± NA | NA ± NA | 3.63 ± 0.961 |
| Month 6 (n=100, 100, 99, 48, 48, NA) | 6.97 ± 0.955 | 7.08 ± 0.959 | 7.10 ± 0.975 | 5.44 ± 1.362 | 6.05 ± 1.373 | NA ± NA |
| Month 9 (n=99, 97, 96, 47, 46, NA) | 7.66 ± 0.947 | 7.74 ± 0.957 | 5.69 ± 0.972 | 5.95 ± 1.355 | 8.93 ± 1.373 | NA ± NA |
| Month 12 (n=96, 96, 94, 44, 44, NA) | 6.13 ± 0.989 | 8.42 ± 0.995 | 6.32 ± 1.012 | 6.19 ± 1.427 | 6.41 ± 1.445 | NA ± NA |
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher role-emotional domain score represents better role-emotional functioning.
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=105, 103,104, NA, NA, 103) | 4.77 ± 0.960 | 3.87 ± 0.971 | 2.93 ± 0.991 | NA ± NA | NA ± NA | 4.52 ± 1.042 |
| Month 3 (n=102, 103, 100, NA, NA, 102) | 4.21 ± 1.010 | 4.82 ± 1.011 | 3.35 ± 1.040 | NA ± NA | NA ± NA | 3.68 ± 1.083 |
| Month 6 (n=100, 100, 98, 48, 48, NA) | 5.67 ± 1.024 | 4.68 ± 1.027 | 4.77 ± 1.051 | 6.34 ± 1.458 | 4.56 ± 1.473 | NA ± NA |
| Month 9 (n=99, 97, 95, 47, 46, NA) | 5.13 ± 1.021 | 6.13 ± 1.030 | 4.87 ± 1.052 | 5.89 ± 1.456 | 6.52 ± 1.478 | NA ± NA |
| Month 12 (n=96, 96, 94, 44, 44, NA) | 5.15 ± 1.048 | 6.73 ± 1.053 | 6.03 ± 1.075 | 4.77 ± 1.509 | 4.94 ± 1.525 | NA ± NA |
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher mental health domain score represents better mental health functioning.
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=105, 103, 104, NA, NA, 103) | 3.32 ± 0.867 | 3.87 ± 0.874 | 2.79 ± 0.895 | NA ± NA | NA ± NA | 1.57 ± 0.952 |
| Month 3 (n=102, 103, 101, NA, NA, 102) | 4.45 ± 0.934 | 4.23 ± 0.932 | 3.95 ± 0.956 | NA ± NA | NA ± NA | 2.62 ± 1.009 |
| Month 6 (n=100, 100, 99, 48, 48, NA) | 6.11 ± 0.951 | 6.38 ± 0.953 | 5.35 ± 0.974 | 3.70 ± 1.354 | 3.41 ± 1.372 | NA ± NA |
| Month 9 (n=99, 97, 96, 47, 46, NA) | 5.79 ± 1.022 | 6.43 ± 1.028 | 4.62 ± 1.048 | 3.57 ± 1.461 | 5.45 ± 1.483 | NA ± NA |
| Month 12 (n=96, 96, 94, 44, 44, NA) | 5.86 ± 1.019 | 6.58 ± 1.022 | 5.86 ± 1.044 | 4.72 ± 1.467 | 4.48 ± 1.483 | NA ± NA |
The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems \[1\], some or moderate problems \[2\], or extreme problems \[3\]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=105, 103, 104, NA, NA, 103) | -0.07 ± 0.042 | -0.19 ± 0.043 | -0.15 ± 0.043 | NA ± NA | NA ± NA | -0.10 ± 0.046 |
| Month 3 (n=101, 103, 101, NA, NA, 102) | -0.28 ± 0.047 | -0.27 ± 0.047 | -0.29 ± 0.048 | NA ± NA | NA ± NA | -0.11 ± 0.050 |
| Month 6 (n=100, 100, 99, 48, 48, NA) | -0.3 ± 0.05 | -0.3 ± 0.05 | -0.2 ± 0.05 | -0.3 ± 0.07 | -0.2 ± 0.07 | NA ± NA |
| Month 9 (n=99, 97, 96, 47, 46, NA) | -0.3 ± 0.05 | -0.3 ± 0.05 | -0.3 ± 0.05 | -0.3 ± 0.07 | -0.3 ± 0.07 | NA ± NA |
| Month 12 (n=96, 96, 94, 44,44, NA) | -0.3 ± 0.05 | -0.3 ± 0.05 | -0.3 ± 0.05 | -0.4 ± 0.07 | -0.3 ± 0.07 | NA ± NA |
The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems \[1\], some or moderate problems \[2\], or extreme problems \[3\]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=105, 102, 104, NA, NA, 103) | -0.11 ± 0.046 | -0.16 ± 0.047 | -0.16 ± 0.047 | NA ± NA | NA ± NA | -0.09 ± 0.050 |
| Month 3 (n=101, 102, 101, NA, NA, 102) | -0.19 ± 0.047 | -0.11 ± 0.047 | -0.18 ± 0.048 | NA ± NA | NA ± NA | -0.12 ± 0.051 |
| Month 6 (n=100, 99, 99, 48, 48, NA) | -0.2 ± 0.04 | -0.3 ± 0.05 | -0.2 ± 0.05 | -0.2 ± 0.06 | -0.3 ± 0.06 | NA ± NA |
| Month 9 (n=99, 97, 96, 47, 46, NA) | -0.2 ± 0.05 | -0.2 ± 0.05 | -0.3 ± 0.05 | -0.2 ± 0.06 | -0.3 ± 0.07 | NA ± NA |
| Month 12 (n=96, 96, 94, 44, 44, NA) | -0.2 ± 0.05 | -0.3 ± 0.05 | -0.3 ± 0.05 | -0.3 ± 0.07 | -0.2 ± 0.07 | NA ± NA |
The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems \[1\], some or moderate problems \[2\], or extreme problems \[3\]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=105, 102, 104, NA, NA, 103) | -0.17 ± 0.043 | -0.19 ± 0.043 | -0.21 ± 0.044 | NA ± NA | NA ± NA | -0.06 ± 0.047 |
| Month 3 (n=101, 102, 101, NA, NA, 102) | -0.24 ± 0.049 | -0.29 ± 0.049 | -0.29 ± 0.049 | NA ± NA | NA ± NA | -0.17 ± 0.052 |
| Month 6 (n=100, 99, 99, 48, 47, NA) | -0.3 ± 0.05 | -0.3 ± 0.05 | -0.4 ± 0.05 | -0.3 ± 0.07 | -0.3 ± 0.07 | NA ± NA |
| Month 9 (n=99, 97, 96, 47, 46, NA) | -0.3 ± 0.05 | -0.4 ± 0.05 | -0.4 ± 0.05 | -0.3 ± 0.07 | -0.4 ± 0.07 | NA ± NA |
| Month 12 (n=96, 96, 94, 44, 44, NA) | -0.3 ± 0.05 | -0.4 ± 0.05 | -0.4 ± 0.05 | -0.3 ± 0.07 | -0.3 ± 0.07 | NA ± NA |
The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems \[1\], some or moderate problems \[2\], or extreme problems \[3\]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=105, 103, 104, NA, NA, 103) | -0.14 ± 0.039 | -0.25 ± 0.040 | -0.19 ± 0.040 | NA ± NA | NA ± NA | -0.08 ± 0.043 |
| Month 3 (n=101, 103, 101, NA, NA, 102) | -0.25 ± 0.044 | -0.27 ± 0.044 | -0.28 ± 0.045 | NA ± NA | NA ± NA | -0.08 ± 0.047 |
| Month 6 (n=100, 100, 99, 48, 48, NA) | -0.3 ± 0.05 | -0.4 ± 0.05 | -0.3 ± 0.05 | -0.3 ± 0.07 | -0.4 ± 0.07 | NA ± NA |
| Month 9 (n=99, 97, 96, 47, 46, NA) | -0.3 ± 0.05 | -0.3 ± 0.05 | -0.3 ± 0.05 | -0.4 ± 0.07 | -0.4 ± 0.07 | NA ± NA |
| Month 12 (n=96, 96, 94, 44, 44, NA) | -0.3 ± 0.05 | -0.4 ± 0.05 | -0.3 ± 0.05 | -0.2 ± 0.07 | -0.3 ± 0.07 | NA ± NA |
The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems \[1\], some or moderate problems \[2\], or extreme problems \[3\]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=105, 103, 104, NA, NA, 103) | -0.25 ± 0.051 | -0.22 ± 0.052 | -0.27 ± 0.053 | NA ± NA | NA ± NA | -0.21 ± 0.056 |
| Month 3 (n=101, 103, 100, NA, NA, 102) | -0.25 ± 0.055 | -0.17 ± 0.055 | -0.32 ± 0.056 | NA ± NA | NA ± NA | -0.21 ± 0.059 |
| Month 6 (n=100, 100, 99, 48, 48, NA) | -0.3 ± 0.05 | -0.3 ± 0.05 | -0.3 ± 0.05 | -0.3 ± 0.08 | -0.2 ± 0.08 | NA ± NA |
| Month 9 (n=99, 97, 96, 47, 46, NA) | -0.3 ± 0.05 | -0.4 ± 0.05 | -0.4 ± 0.06 | -0.2 ± 0.08 | -0.3 ± 0.08 | NA ± NA |
| Month 12 (n=96, 96, 94, 44, 44, NA) | -0.3 ± 0.05 | -0.4 ± 0.05 | -0.4 ± 0.06 | -0.2 ± 0.08 | -0.3 ± 0.08 | NA ± NA |
The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems \[1\], some or moderate problems \[2\], or extreme problems \[3\]) within a particular EQ-5D dimension. Standard vertical 0 (worst imaginable health state) to 100 mm (best imaginable health state) visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state; higher scores indicate a better health state, with a higher value representing better health status.
| mm | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=105, 103, 104, NA, NA, 103) | 10.75 ± 1.859 | 10.81 ± 1.880 | 10.27 ± 1.917 | NA ± NA | NA ± NA | 6.59 ± 2.027 |
| Month 3 (n=101, 103, 101, NA, NA, 101) | 14.00 ± 2.100 | 15.83 ± 2.092 | 13.10 ± 2.138 | NA ± NA | NA ± NA | 6.37 ± 2.242 |
| Month 6 (n=100, 100, 99, 48, 48, NA) | 19.5 ± 2.08 | 15.7 ± 2.09 | 15.5 ± 2.12 | 14.7 ± 2.97 | 16.6 ± 3.00 | NA ± NA |
| Month 9 (n=99, 97, 96, 47, 46, NA) | 19.2 ± 2.21 | 15.9 ± 2.23 | 18.2 ± 2.26 | 12.8 ± 3.16 | 21.5 ± 3.21 | NA ± NA |
| Month 12 (n=96, 96, 94, 44, 44, NA) | 20.7 ± 2.09 | 19.8 ± 2.09 | 16.5 ± 2.14 | 16.0 ± 3.02 | 19.8 ± 3.05 | NA ± NA |
FACIT-F is a 13-item questionnaire, with each item scored on a 5-point scale ranging from 0 (not at all) to 4 (very much). Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0 to 52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better fatigue status.
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=105, 103, 104, NA, NA, 103) | 5.2 ± 0.77 | 4.4 ± 0.78 | 4.2 ± 0.79 | NA ± NA | NA ± NA | 2.7 ± 0.84 |
| Month 3 (102, 102, 101, NA, NA, 102) | 7.0 ± 0.85 | 6.0 ± 0.85 | 6.0 ± 0.87 | NA ± NA | NA ± NA | 3.3 ± 0.91 |
| Month 6 (n=100, 100, 99,48, 48, NA) | 7.9 ± 0.89 | 8.0 ± 0.89 | 6.5 ± 0.91 | 6.5 ± 1.26 | 7.2 ± 1.28 | NA ± NA |
| Month 9 (n=99, 97, 96, 47, 46, NA) | 7.9 ± 0.92 | 7.4 ± 0.92 | 6.5 ± 0.94 | 5.5 ± 1.31 | 8.4 ± 1.33 | NA ± NA |
| Month 12 (n=96, 96, 94, 44, 44, NA) | 8.5 ± 0.95 | 8.4 ± 0.95 | 6.9 ± 0.97 | 5.7 ± 1.36 | 7.6 ± 1.38 | NA ± NA |
FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better (less) fatigue experience.
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=105, 103, 104, NA, NA, 103) | 2.4 ± 0.35 | 2.1 ± 0.35 | 2.1 ± 0.36 | NA ± NA | NA ± NA | 1.2 ± 0.38 |
| Month 3 (n=102, 102, 101, NA, NA, 102) | 3.3 ± 0.38 | 2.8 ± 0.38 | 2.9 ± 0.39 | NA ± NA | NA ± NA | 1.6 ± 0.41 |
| Month 6 (n=100, 100, 99,48, 48, NA) | 3.6 ± 0.40 | 3.3 ± 0.40 | 3.2 ± 0.41 | 3.0 ± 0.57 | 3.3 ± 0.58 | NA ± NA |
| Month 9 (n=99, 97, 96, 47, 46, NA) | 3.6 ± 0.42 | 3.3 ± 0.42 | 3.3 ± 0.43 | 2.7 ± 0.59 | 3.9 ± 0.60 | NA ± NA |
| Month 12 (n=96, 96, 94, 44, 44, NA) | 3.9 ± 0.44 | 3.7 ± 0.44 | 3.2 ± 0.45 | 2.7 ± 0.63 | 3.4 ± 0.63 | NA ± NA |
FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better (less) fatigue impact on daily functioning.
| Units on a scale | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=105, 103, 104, NA, NA, 103) | 2.9 ± 0.47 | 2.3 ± 0.48 | 2.1 ± 0.49 | NA ± NA | NA ± NA | 1.5 ± 0.52 |
| Month 3 (n=102, 102, 101, NA, NA, 102) | 3.8 ± 0.52 | 3.2 ± 0.52 | 3.2 ± 0.53 | NA ± NA | NA ± NA | 1.8 ± 0.56 |
| Month 6 (n=100, 100, 99,48, 48, NA) | 4.3 ± 0.53 | 4.7 ± 0.53 | 3.4 ± 0.54 | 3.5 ± 0.75 | 4.0 ± 0.76 | NA ± NA |
| Month 9 (n=99, 97, 96, 47, 46, NA) | 4.3 ± 0.55 | 4.1 ± 0.55 | 3.3 ± 0.56 | 2.8 ± 0.78 | 4.6 ± 0.80 | NA ± NA |
| Month 12 (n=96, 96, 94, 44, 44, NA) | 4.6 ± 0.57 | 4.7 ± 0.57 | 3.7 ± 0.58 | 2.9 ± 0.82 | 4.3 ± 0.82 | NA ± NA |
BASDAI is a validated self-assessment tool used to determine disease activity in participants with ankylosing spondylitis. Utilizing a visual analog scale of 0-100mm (0=none and 100=very severe) participants answer 6 questions measuring discomfort, pain, and fatigue. The final BASDAI score averages the individual assessments for a final score ranging 0-10cm, with higher scores representing more severe ankylosing spondylitis disease activity.
| cm | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Placebo |
|---|---|---|---|---|---|---|
| Month 1 (n=24, 21, 10, NA, NA, 22) | -1.23 ± 0.537 | -1.60 ± 0.508 | -2.30 ± 0.673 | NA ± NA | NA ± NA | -1.27 ± 0.581 |
| Month 3 (n=24, 21, 10, NA, NA, 22) | -1.83 ± 0.579 | -2.78 ± 0.559 | -2.93 ± 0.753 | NA ± NA | NA ± NA | -1.60 ± 0.624 |
| Month 6 (n=23, 21, 10, 9, 11, NA) | -2.24 ± 0.580 | -2.35 ± 0.560 | -3.58 ± 0.758 | -2.85 ± 0.778 | -3.31 ± 0.744 | NA ± NA |
| Month 9 (n=23, 20, 10, 9, 9, NA) | -2.06 ± 0.575 | -2.71 ± 0.558 | 2.66 ± 0.747 | -3.00 ± 0.770 | -3.35 ± 0.761 | NA ± NA |
| Month 12 (n=23, 19, 10, 9, 9, NA) | -2.50 ± 0.594 | -3.30 ± 0.587 | -2.42 ± 0.779 | -2.31 ± 0.808 | -2.67 ± 0.806 | NA ± NA |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tofacitinib, 5 mg, Twice Daily | — | 8/107 (7.5%) | 31/107 (29%) |
| Tofacitinib, 10 mg, Twice Daily | — | 4/104 (3.8%) | 43/104 (41.3%) |
| Adalimumab, 40 mg, Every 2 Weeks | — | 9/106 (8.5%) | 43/106 (40.6%) |
| Placebo/Tofacitinib, 5 mg, Twice Daily | — | 3/52 (5.8%) | 15/52 (28.8%) |
| Placebo/Tofacitinib, 10 mg, Twice Daily | — | 4/53 (7.5%) | 22/53 (41.5%) |
| Event | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily |
|---|---|---|---|---|---|
| Cardiac arrestCardiac disorders | 0/107 | 0/104 | 0/106 | 1/52 | 0/53 |
| AppendicitisInfections and infestations | 0/107 | 0/104 | 0/106 | 1/52 | 0/53 |
| PneumoniaInfections and infestations | 0/107 | 0/104 | 0/106 | 1/52 | 0/53 |
| Abdominal herniaGastrointestinal disorders | 0/107 | 0/104 | 0/106 | 0/52 | 1/53 |
| DiverticulumGastrointestinal disorders | 0/107 | 0/104 | 0/106 | 0/52 | 1/53 |
| SpondylolisthesisMusculoskeletal and connective tissue disorders | 0/107 | 0/104 | 0/106 | 0/52 | 1/53 |
| NephropathyRenal and urinary disorders | 0/107 | 0/104 | 0/106 | 0/52 | 1/53 |
| Uterine polypReproductive system and breast disorders | 0/107 | 0/104 | 0/106 | 0/52 | 1/53 |
| Deep vein thrombosisVascular disorders | 0/107 | 0/104 | 0/106 | 0/52 | 1/53 |
| InfluenzaInfections and infestations | 0/107 | 1/104 | 0/106 | 0/52 | 0/53 |
| Event | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 8/107 | 12/104 | 11/106 | 4/52 | 4/53 |
| Upper respiratory tract infectionInfections and infestations | 10/107 | 11/104 | 8/106 | 5/52 | 5/53 |
| HeadacheNervous system disorders | 5/107 | 11/104 | 7/106 | 2/52 | 4/53 |
| Blood creatine phosphokinase increasedInvestigations | 5/107 | 5/104 | 3/106 | 1/52 | 5/53 |
| Urinary tract infectionInfections and infestations | 2/107 | 4/104 | 4/106 | 1/52 | 4/53 |
| Alanine aminotransferase increasedInvestigations | 3/107 | 3/104 | 8/106 | 3/52 | 1/53 |
| PharyngitisInfections and infestations | 5/107 | 6/104 | 7/106 | 0/52 | 3/53 |
| Aspartate aminotransferase increasedInvestigations | 0/107 | 1/104 | 7/106 | 1/52 | 1/53 |
| Spinal painMusculoskeletal and connective tissue disorders | 2/107 | 1/104 | 3/106 | 3/52 | 0/53 |
| Abdominal painGastrointestinal disorders | 1/107 | 1/104 | 2/106 | 0/52 | 3/53 |
All participants who received at least 1 dose of study drug.
| Age, Continuous(Years) | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Total |
|---|---|---|---|---|---|---|
| Mean | 49.4 ± 12.6 | 46.9 ± 12.4 | 47.4 ± 11.3 | 46.1 ± 10.4 | 49.3 ± 13.8 | 47.9 ± 12.1 |
| Sex: Female, Male(Participants) | Tofacitinib, 5 mg, Twice Daily | Tofacitinib, 10 mg, Twice Daily | Adalimumab, 40 mg, Every 2 Weeks | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Total |
|---|---|---|---|---|---|---|
| Female | 57 | 62 | 50 | 28 | 28 | 225 |
| Male | 50 | 42 | 56 | 24 | 25 | 197 |
Showing the first 100 of 123 sites across 16 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests
Ran from Jan 2014 to primary completion in Dec 2015, 22 months.
Results were first posted in Jul 2017, 1 year 6 months after primary completion.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 22 months is below that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib